EMBC News and Press, Embecta Corp. From 01/24/23

PARSIPPANY, N.J., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal first quarter 2023 financial results, provide an operational update, and...

Summary Medical devices company Becton Dickinson spun off Embecta last year. After an uneventful start, shares plunged in December on a bad earnings report. Even after the decline, I'm not sure the value proposition is clear enough to warrant buying just yet. F...

The law firm of Kirby McInerney LLP is investigating potential claims against Embecta Corporation (“Embecta” or the “Company”) (NASDAQ: EMBC ). The investigation concerns whether Embecta and/or certain of its officers have violated the federal securities laws a...

SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose materi...

Summary Becton, Dickinson had a flat year in 2022. Compared to the market, that was a strong result. Over the longer-term, Becton, Dickinson has been a solid compounder, but returns have lost some steam over the past five years. I believe the company can get back on track, and that ...

Embecta Corp. (EMBC) Q4 2022 Earnings Conference Call December 20, 2022 08:00 ET Company Participants Pravesh Khandelwal - Vice President of Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Particip...

Shares of Embecta (NASDAQ: EMBC.V) were sinking 12.4% lower as of 10:52 a.m. ET on Tuesday. The decline came after the diabetes care provider announced its fourth-quarter results earlier in the morning. Embecta reported Q4 revenue of $274.6 million, down 8.7% year over year. This topp...

Embecta press release ( NASDAQ: EMBC ): Q4 GAAP EPS of -$0.30. Revenue of $274.6M (-8.7% Y/Y). For further details see: Embecta GAAP EPS of -$0.30, revenue of $274.6M

PARSIPPANY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three and twelve month periods ended September 30, 2022. “2022 ...

Embecta ( NASDAQ: EMBC ) declares $0.15/share quarterly dividend , in line with previous. Forward yield 1.85% Payable Jan. 11; for shareholders of record Dec. 30; ex-div Dec. 29. See EMBC Dividend Scorecard, Yield Chart, & Dividend Growth. For further det...